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Abstract
Purpose Concomitant treatment with the glucose-lowering
drug metformin and the platelet aggregation inhibitor
dipyridamole often occurs in patients with type 2 diabetes
mellitus who have suffered a cerebrovascular event. The gas-
trointestinal uptake of metformin is mediated by the human
equilibrative nucleoside transporter 4 (ENT4), which is
inhibited by dipyridamole in preclinical studies. We hypothe-
sized that dipyridamole lowers the plasma exposure to
metformin.
Methods Eighteen healthy volunteers (mean age 23 years; 9
male) were randomized in an open-label crossover study.
Subjects were allocated to treatment with metformin 500 mg
twice daily in combination with dipyridamole slow-release
200 mg twice daily or to metformin alone for 4 days. After a
washout period of 10 days, the volunteers were crossed over
to the alternative treatment arm. Blood samples were collected
during a 10-h period after intake of the last metformin dose.
The primary endpoint was the area under the plasma
concentration-time curve (AUC0–12h) and the maximum plas-
ma metformin concentration (Cmax).
Results In healthy subjects, dipyridamole did not significantly
affect Cmax nor AUC0–12h of metformin under steady-state
conditions.
Conclusions Previous in vitro studies report that
dipyridamole inhibits the ENT4 transporter that mediates gas-
trointestinal uptake of metformin. In contrast, co-
administration of dipyridamole at therapeutic dosages to
healthy volunteers does not have a clinically relevant effect
on metformin plasma steady-state exposure. This observation
is reassuring for patients who are treated with this combination
of drugs.
Keywords Metformin . Dipyridamole . ENT4 . PMAT .
Drug interaction . Pharmacokinetics
Introduction
Patients with type 2 diabetes mellitus are at increased risk for
cardiovascular disease and associated cardiovascular events
[1]. The incidence of ischemic stroke is significantly increased
in these patients [2].Metformin, a biguanide glucose-lowering
agent, is the first line oral treatment option in patients with
type 2 diabetes mellitus [3]. The primary mechanism of action
is inhibition of hepatic gluconeogenesis [4]. In addition, there
is preclinical and clinical evidence that metformin has direct
cardiovascular protective properties independent of its
glucose-lowering action [5].
Dipyridamole is registered for the secondary prevention of
cerebral ischemia in combination with acetylsalicylic acid,
since studies have shown that dipyridamole added to
acetylsalicylic acid reduces the incidence of myocardial in-
farction, stroke, or cardiovascular death [6]. Therefore, con-
comitant treatment with metformin and dipyridamole often
occurs in patients with type 2 diabetes who have suffered a
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cerebrovascular event, and potential pharmacokinetic interac-
tions between these drugs are highly relevant.
Metformin is a highly hydrophilic compound with a net
positive charge at physiologic pH and its absorption, dis-
tribution, and elimination are dependent on active trans-
port by several carrier-mediated transporters [7]. The up-
take of metformin from the gastrointestinal tract is medi-
ated, at least in part, by the human equilibrative nucleo-
side transporter 4 (ENT4; gene SLC29A4), also known as
the plasma membrane monoamine transporter (PMAT) [7,
8]. ENT4 is localized on the apical membrane of
enterocyte villus tips and exhibits great sensitivity to
pH, with an optimal activity at a pH of approximately
6.0 [8, 9]. Renal excretion of metformin is mediated by
the human organic cation transporter hOCT2, which is
expressed on the basolateral membrane of proximal tubu-
lar cells, and by multidrug and toxin extrusion trans-
porters (MATE1 and to a lesser extent MATE2K), which
are present in the apical membrane [7]. Uptake into hepa-
tocytes occurs via hOCT1 and hOCT3, and excretion into
bile is mediated by MATE1 [7, 10]. This is corroborated
by the findings of a profound reduction in the apparent
volume of distribution of metformin in OCT1- and OCT3-
knockout mice [11, 12].
The transport characteristics of ENT4 have been stud-
ied in various in vitro models [9, 13]. Substrate transport
by ENT4 (tested for adenosine and 1-methyl-4-
phenylpyridinium) is s ignif icant ly inhibi ted by
dipyridamole with an IC50 value of approximately
5 μM, which is in the range of the plasma concentration
during normal therapeutic use of dipyridamole [14].
Therefore, by inhibition of the apical ENT4, concomitant
treatment with dipyridamole might result in a lower bio-
availability and plasma concentration of metformin.
The aim of this study was to determine whether concomi-
tant use of dipyridamole reduces the gastrointestinal absorp-
tion of metformin in healthy subjects.
Methods
Participants
Healthy male and female participants between the ages of
18 and 50 years were eligible for enrollment. The includ-
ed participants had to be in good health, free from cardio-
vascular disease, diabetes mellitus and hypertension (sys-
tolic blood pressure ≥140 mmHg and/or diastolic
≥90 mmHg), and non-smoking. We excluded individuals
with renal dysfunction (GFR MDRD <60 ml/min/
1.73 m2), ECG abnormalities, and those who were taking
concomitant medication. Oral contraception use by female
participants was permitted.
Ethics statement
The study was approved by the local ethics committee and
was performed in the Radboud University Medical Center in
compliance with the recommendations of the Declaration of
Helsinki. We obtained written informed consent from all vol-
unteers before participation. Preparation, conduct, and analy-
sis of this trial complied with Good Clinical Practice guide-
lines. This trial was prospectively registered at www.
clinicaltrials.gov (NCT01613755).
Experimental design
In a prospective randomized open-label two-period crossover
study, subjects were allocated to treatment with either metfor-
min hydrochloride 500 mg (Mylan, Bunschoten,
The Netherlands) twice daily in combination with
dipyridamole slow release 200 mg (Boehringer Ingelheim,
Alkmaar, The Netherlands) twice daily, both for 4 days to
ensure a steady-state plasma concentration, or to metformin
500mg alone twice daily for 4 days. After a washout period of
10 days, the volunteers were crossed over to the alternative
treatment arm. An independent researcher performed simple
random allocation by the use of sealed envelopes. We studied
the interaction between metformin and dipyridamole at
steady-state for both drugs, because this more accurately re-
flects common clinical practice. To demonstrate that a steady-
state plasma concentration was reached, blood was drawn in
the morning of the third treatment day and fourth day, imme-
diately before intake of the morning dose of dipyridamole and
1 h later, which was just before the morning dose of metfor-
min, to determine the trough plasma concentration of
dipyridamole and metformin, respectively. On the fourth treat-
ment day, the subjects attended our research center for the
pharmacokinetic studies. All subjects had to abstain from al-
cohol consumption for at least 24 h before the measurements,
since alcohol can inhibit ENT transport [15]. The morning
doses of both metformin and dipyridamole on the days of
serial blood sampling were given under supervision at our
research center. To ensure optimal dipyridamole exposure to
the gastrointestinal ENT transporters, the dipyridamole dose
was administered 1 h before the metformin dose. After intake
of the dipyridamole dose, the volunteers were allowed to have
breakfast. Lunch was served no earlier than 4 h after metfor-
min dosing and participants received a snack no earlier than
2 h after lunch.
Pharmacokinetic sampling and safety assessments
Blood samples for the assessment of pharmacokinetic param-
eters of metformin were collected during a 10-h period at t=0
(pre-dose), 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, and 10 h after the
intake of the morning dose of metformin. These time points
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were chosen because the Tmax of metformin is approximately
2.5 h. Blood samples were collected in heparinized tubes and
centrifuged for 10 min at 3000 rpm (1700g) at 20 °C. Plasma
was transferred to polypropylene tubes and stored at −80 °C
until further analysis. Subjects were asked about the occur-
rence of adverse events at each visit day.
Compliance
Participants were asked to return the package of their study
medication on both study days. Compliance to medication
was monitored by counting the remaining tablets on each
study day.
Analysis of metformin and dipyridamole concentrations
in plasma
See supplement.
Pharmacokinetic analysis
Pharmacokinetic parameters for metformin were calculated by
noncompartmental methods using the WinNonlin software
package (version 6.3; Pharsight, Mountain View, CA) and
the linear log-trapezoidal rule. Based on the individual plasma
concentration-time data, the following pharmacokinetic pa-
rameters of metformin were determined: AUC0–10h, the ex-
trapolated AUC from 0 to 12 h after intake (AUC0–12h),
Cmax, Tmax, V/F, CL/F and the apparent elimination half-life
(T1/2). C12h was extrapolated by log-linear extrapolation using
lambda z from the last measured concentration (C10h).
Pharmacokinetic parameters are reported as geometric means
with CV%. Geometric mean ratios (GMRs) of the pharmaco-
kinetic parameters of the test treatment [combination metfor-
min+dipyridamole] versus the reference treatment [metfor-
min alone] and 90 % CI were calculated after log transforma-
tion of within-subject ratios using a mixed effects bioequiva-
lence module in WinNonlin/Phoenix.
Sample size and statistical analysis
For the identification of a clinically relevant drug interaction,
the bioequivalence approach was used, as described previous-
ly [16]. The main pharmacokinetic parameter to be evaluated
in this respect is the exposure to metformin, expressed as
AUC0–12h. This pharmacokinetic parameter and the Cmax are
considered to be the primary measures in this study. Sample
size calculation was performed using the method for two-
period designs of Diletti et al. [17]. The required sample size
was calculated (power of 80 %) assuming no difference in the
AUC of metformin with or without dipyridamole and an esti-
mated intra-subject coefficient of variation of the AUC values
for metformin of 19 %, as reported in other pharmacokinetic
studies with metformin in healthy volunteers [7, 18]. The re-
quired number of participants was 16. Taking dropouts into
account, a total of 18 subjects were included.
Results
Baseline characteristics
We included 18 subjects. One participant withdrew during the
study due to difficulties with venous sampling. This partici-
pant was only included in the safety analysis. Therefore, 17
subjects finished the trial protocol (Suppl. Fig. 1) and were
included in the analysis of pharmacokinetic parameters.
Baseline characteristics are presented in Table 1.
Compliance
The compliance with both metformin and dipyridamole treat-
ment of all subjects was excellent, as indicated by their state-
ments about the intake of the drug doses and the number of
tablets counted on each visit day. All subjects took their study
medication according to protocol, without missing a dose.
Evaluation of steady state
Mean (SD) trough plasma concentrations of both metformin
and dipyridamole collected on the third treatment day and the
morning of the fourth treatment day (day of serial blood
Table 1 Baseline characteristics
Age, years 23 (range 20–25)
Gender
Male 9 (53 %)
Female 8 (47 %)
Body mass index, kg/m2 22.1 ± 3.0
Blood pressure, mmHg
Systolic 131 ± 9
Diastolic 80± 6
Heart rate, beats/min 68± 8
Smoking 0 (0 %)
Alcohol consumption
≤2 units per day 15 (88 %)
>2 units per day 2 (12 %)
Laboratory values at screening
Glucose, mmol/L 5.1 ± 1.0
Creatinin, μmol/L 73± 13
GFR (MDRD), ml/min/1.73 m2 81± 14
Data are mean ± SD (except for age, mean (range)) or number (%) unless
stated otherwise
GRF glomerular filtration rate, MDRD modification of diet in renal
disease
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collection) showed that subjects were adherent and that steady
state conditions for both metformin and dipyridamole were
reached (Supplementary Table 1).
Metformin pharmacokinetics
The pharmacokinetic parameters and the plasma
concentration-time curves of metformin in the presence and
absence of dipyridamole are shown in Table 2 and Fig. 1. All
90 % confidence intervals fell within the 80–125 % bioequiv-
alence criterium. This means that dipyridamole did not affect
Cmax and AUC0–12h of metformin.
Adverse events and safety assessments
The study medication was generally well tolerated, and no
serious adverse events occurred. In the metformin-
dipyridamole treatment arm, 13 subjects (77 %) reported
headache and 8 subjects (47 %) reported mild, self-limiting
gastrointestinal discomfort, mostly diarrhea. One person de-
veloped a phlebitis of his arm after removal of the cannula. In
the metformin-only group, 8 subjects (47 %) reported mild
and self-limiting gastrointestinal discomfort, mostly diarrhea.
There was no headache reported in this group. One subject
reported the occurrence of vivid nightmares, considered not
related to the study medication. Adverse events occurred
mostly within several hours after start of the study medication,
were mild (all were classified as grade 1), and self-limiting.
Discussion
We tested the hypothesis that dipyridamole reduces the bio-
availability of metformin after oral administration by inhibi-
tion of the luminal ENT4 in the small intestine. In a classical
randomized crossover pharmacokinetic interaction study in
healthy subjects, there was no effect of co-administered
slow-release dipyridamole on Cmax and AUC0–12h of metfor-
min. As such, we can conclude that concomitant treatment
with slow-release dipyridamole does not relevantly affect the
plasma exposure to metformin. This finding is of great impor-
tance since many patients with type 2 diabetes mellitus who
have suffered a stroke or transient ischemic attack are being
treated with both of these drugs.
Our hypothesis that dipyridamole limits intestinal absorp-
tion of metformin after oral intake was driven by the following
observations. First, ENT4 is important in the luminal uptake
of metformin [7, 8]. Secondly, dipyridamole significantly in-
hibits ENT4-mediated substrate transport with relevant IC50
values [14]. Thirdly, genetic variations in the gene encoding
ENT4 affect steady-state plasma levels of metformin, empha-
sizing that this transporter is important for metformin uptake
[19]. Based on these findings, concomitant use of metformin
and dipyridamole may result in lower systemic exposure to
metformin which may impact on serum glucose.
In contrast to our hypothesis, we observed no significant
impact of dipyridamole on plasma exposure to metformin in
clinical relevant doses, as reflected by AUC0–12h and Cmax.
There are several potential explanations as to why
dipyridamole does not limit intestinal absorption of metfor-
min. First, a reduced ENT4-mediated uptake of metformin
might be compensated for by an increased absorption by al-
ternative intestinal transporters that are not affected by
dipyridamole. Human small intestine contains detectable
Table 2 Comparison of steady
state pharmacokinetic parameters
of metformin with or without co-
administration of dipyridamole to
healthy volunteers
Pharmacokinetic
parameter
Metformin (GM
(CV%))
Metformin + dipyridamole (GM
(CV%))
GMR (90 %
CI)
AUC0-12h (ng×h/mL) 7600 (19) 7600 (19) 100 (93–108)
AUC0-10h (ng×h/mL) 7100 (18) 7000 (19) 99 (93–107)
CL/F (L/h) 66 (19) 66 (19) 100 (93–107)
V/F (L) Winnonlin 340 (26) 370 (40) 108 (96–120)
T1/2, desc (h) Winnonlin 3.6 (25) 3.9 (36) 108 (99–118)
Tmax (h) 3 (1–4) 3.5 (2.5–6)
Cmax (ng/mL) 1100 (19) 1100 (19) 101 (95–107)
Results of noncompartmental analysis; for Tmax, median and range are reported
GM geometric mean
Fig. 1 Plasma metformin concentrations (geometric mean ±CV%)
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messenger RNA (mRNA) expression of OCT1-3, OCTN1-2,
and ENT4 [8, 20, 21]. Based on earlier literature, only OCT3
and ENT4 appear to be localized on the apical border of the
enterocytes and could therefore play a role in intestinal ab-
sorption. More recently, apical expression of the serotonin
reuptake transporter (SERT) and OCTN1 in enterocytes was
demonstrated, which may also transport metformin [22–24].
An alternative explanation was provided by Proctor et al., who
reported significant paracellular uptake of metformin [25].
These experiments, however, were performed in vitro in
Caco-2 cells, which differ importantly from the physiological
in vivo situation in human small intestine. Finally, although
the IC50 value of the ENT4 for dipyridamole is in the con-
centration range that is obtained in plasma after oral
dipyridamole administration, we are not informed about the
luminal concentration of dipyridamole at the site of metformin
absorption. A potential mechanism that could increase absorp-
tion of metformin could be the modulation of the intraluminal
pH by dipyridamole: the extended release preparation of
dipyridamole contains tartaric acid. As dipyridamole is a poor-
ly soluble weak base that shows pH-dependent absorption,
this formulation should provide a sufficiently acidic local mi-
lieu within the basic pH environment of the intestine to pro-
mote absorption [26]. Theoretically, this could have been fa-
vorable for ENT4-mediated metformin transport, which is
greatly stimulated by acidic pH [8].
Study medication was well tolerated and subjects experi-
enced only mild side effects. The occurrence of headache was
associated with use of dipyridamole, while gastrointestinal
discomfort was related to metformin [27, 28]. This mainly
involved mild and self-limiting diarrhea in the first days of
metformin treatment. We think it is unlikely that a potentially
shorter gastrointestinal passage time relevantly affected the
results of our study, since diarrhea occurred to a similar extent
in both treatment arms, and in most patients, it was restricted
to the first few days of metformin intake.
There are a few potential limitations of our study. First,
genetic variation in the genes encoding for the various met-
formin transporters, including ENT4 and OCT1-2, have been
linked previously to the altered pharmacokinetic and pharma-
codynamic response tometformin, but we did not perform any
genotyping of the relevant transporters. Secondly, we did not
collect urine from the subjects. This would have enabled us to
more directly estimate the effect of dipyridamole on metfor-
min elimination.
In conclusion, co-administration of dipyridamole at thera-
peutic dosages to healthy volunteers does not have a clinically
relevant effect on metformin plasma steady-state exposure.
This observation is reassuring for patients who are treated with
this combination of drugs.
Acknowledgments We thank the healthy volunteers for participating in
this trial and the study personnel at the Clinical Research Center
Nijmegen for their help in conducting the study. We also thank A.
Bilos, department of Pharmacology-Toxicology, Radboud university
medical center, for his technical assistance in determination of plasma
dipyridamole concentrations.
Compliance with ethical standards
Ethics statement The study was approved by the local ethics commit-
tee and was performed in the Radboud University Medical Center in
compliance with the recommendations of the Declaration of Helsinki.
We obtained written informed consent from all volunteers before partic-
ipation. Preparation, conduct, and analysis of this trial complied with
Good Clinical Practice guidelines. This trial was prospectively registered
at www.clinicaltrials.gov (NCT01613755).
Conflicts of interest All authors have completed the Unified
Competing Interest Form at http://www.icmje.org/coi_disclosure.pdf
(available on request from the corresponding author). This work was
supported by grant 2010B195 from the Dutch Heart Foundation to
NPR and GAR. GAR has served in a scientific advisory board of
Novartis. NPR is a recipient of a clinical fellowship from the Dutch
Organisation for Health Research and Development (ZonMw). NPR
has received an unrestricted grant from AstraZeneca unrelated to the
current work and has served in a scientific advisory board of
AstraZeneca. For the remaining authors none were declared.
Funding This work was supported by grant 2010B195 from the Dutch
Heart Foundation to NPR and GAR.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Nicholls SJ, Tuzcu EM, Kalidindi S et al (2008) Effect of diabetes
on progression of coronary atherosclerosis and arterial remodeling:
a pooled analysis of 5 intravascular ultrasound trials. J Am Coll
Cardiol 52(4):255–262
2. Shah AD, Langenberg C, Rapsomaniki E et al (2015) Type 2 dia-
betes and incidence of cardiovascular diseases: a cohort study in 1.9
million people. Lancet Diabetes Endocrinol 3(2):105–113
3. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P
(2012) Oral pharmacologic treatment of type 2 diabetes mellitus:
a clinical practice guideline from the American College of
Physicians. Ann Intern Med 156(3):218–231
4. Miller RA, Chu Q, Xie J, Foretz M, Viollet B, BirnbaumMJ (2013)
Biguanides suppress hepatic glucagon signalling by decreasing pro-
duction of cyclic AMP. Nature 494(7436):256–260
5. Riksen NP, Tack CJ (2014) The cardiovascular effects of metfor-
min: lost in translation? Curr Opin Lipidol 25(6):446–451
6. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A (2006)
Aspirin plus dipyridamole versus aspirin alone after cerebral ischae-
mia of arterial origin (ESPRIT): randomised controlled trial. Lancet
367(9523):1665–1673
7. Graham GG, Punt J, Arora M et al (2011) Clinical pharmacokinet-
ics of metformin. Clin Pharmacokinet 50(2):81–98
Eur J Clin Pharmacol (2016) 72:725–730 729
8. Zhou M, Xia L, Wang J (2007) Metformin transport by a newly
cloned proton-stimulated organic cation transporter (plasma mem-
brane monoamine transporter) expressed in human intestine. Drug
Metab Dispos 35(10):1956–1962
9. Barnes K, Dobrzynski H, Foppolo S et al (2006) Distribution and
functional characterization of equilibrative nucleoside transporter-
4, a novel cardiac adenosine transporter activated at acidic pH. Circ
Res 99(5):510–519
10. Chen S, Zhou J, Xi M et al (2013) Pharmacogenetic variation and
metformin response. Curr Drug Metab 14(10):1070–1082
11. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH,
Sugiyama Y (2002) Involvement of organic cation transporter 1
in hepatic and intestinal distribution of metformin. J Pharmacol
Exp Ther 302(2):510–515
12. Chen EC, Liang X, Yee SW et al (2015) Targeted disruption of
organic cation transporter 3 (Oct3) attenuates the pharmacologic
response to metformin. Mol Pharmacol 88(1):75–83
13. Zhou M, Duan H, Engel K, Xia L, Wang J (2010) Adenosine
transport by plasma membrane monoamine transporter: reinvesti-
gation and comparison with organic cations. Drug Metab Dispos
38(10):1798–1805
14. Riksen NP, Oyen WJ, Ramakers BP et al (2005) Oral therapy with
dipyridamole limits ischemia-reperfusion injury in humans. Clin
Pharmacol Ther 78(1):52–59
15. Nagy LE, Diamond I, Casso DJ, Franklin C, Gordon AS
(1990) Ethanol increases extracellular adenosine by inhibiting
adenosine uptake via the nucleoside transporter. J Biol Chem
265(4):1946–1951
16. U.S. Food and Drug Administration (2010) Guidance for industry.
Statistical approaches to establishing bioequivalence. http://www.
fdagov/downloads/drugs/guidancecomplianeregulatory
information/guidances/ucm070244pdf US Food and Drug
Administration, Washington, DC
17. Diletti E, Hauschke D, Steinijans VW (1991) Sample size determi-
nation for bioequivalence assessment by means of confidence in-
tervals. Int J Clin Pharmacol Ther Toxicol 29(1):1–8
18. Timmins P, Donahue S, Meeker J, Marathe P (2005) Steady-state
pharmacokinetics of a novel extended-release metformin formula-
tion. Clin Pharmacokinet 44(7):721–729
19. Christensen MM, Brasch-Andersen C, Green H et al (2011) The
pharmacogenetics of metformin and its impact on plasma metfor-
min steady-state levels and glycosylated hemoglobin A1c.
Pharmacogenet Genomics 21(12):837–850
20. Muller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch
M (2005) Drug specificity and intestinal membrane localization of
human organic cation transporters (OCT). Biochem Pharmacol
70(12):1851–1860
21. Meier Y, Eloranta JJ, Darimont J et al (2007) Regional distribution
of solute carrier mRNA expression along the human intestinal tract.
Drug Metab Dispos 35(4):590–594
22. Han TK, ProctorWR, Costales CL, Cai H, Everett RS, Thakker DR
(2015) Four cation-selective transporters contribute to apical uptake
and accumulation of metformin in Caco-2 cell monolayers. J
Pharmacol Exp Ther 352(3):519–528
23. Sugiura T, Kato S, Shimizu T et al (2010) Functional expression of
carnitine/organic cation transporter OCTN1/SLC22A4 in mouse
small intestine and liver. Drug Metab Dispos 38(10):1665–1672
24. Nakamichi N, Shima H, Asano S et al (2013) Involvement of
carnitine/organic cation transporter OCTN1/SLC22A4 in gastroin-
testinal absorption of metformin. J Pharm Sci 102(9):3407–3417
25. Proctor WR, Bourdet DL, Thakker DR (2008) Mechanisms under-
lying saturable intestinal absorption of metformin. Drug Metab
Dispos 36(8):1650–1658
26. Derendorf H, VanderMaelen CP, Brickl RS, MacGregor TR, Eisert
W (2005) Dipyridamole bioavailability in subjects with reduced
gastric acidity. J Clin Pharmacol 45(7):845–850
27. Theis JG, Deichsel G, Marshall S (1999) Rapid development of
tolerance to dipyridamole-associated headaches. Br J Clin
Pharmacol 48(5):750–755
28. Nasri H, Rafieian-Kopaei M (2014)Metformin: current knowledge.
J Res Med Sci 19(7):658–664
730 Eur J Clin Pharmacol (2016) 72:725–730
